Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 12;20:112. doi: 10.1186/s13058-018-1028-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 7 — Higher expression of Nogo-B receptor (NgBR) is associated with poor outcome in patients with estrogen receptor alpha (ERα) positive breast cancer. a Immunohistocheical (IHC) staining of NgBR, Nogo-B and survivin in 22 samples of breast cancer tissue. Images were taken using an Olympus microscope with × 20 lens. Scale bar 100 μm. b Relapse-free survival (RFS) in patients with ERα-positive breast cancer or endocrine therapy-treated patients. NgBR (NUS1) mRNA expression data were retrieved from a gene-expression profiling dataset (225071_x from Kaplan–Meier Plot database) of 755 cases of ERα-positive breast cancer and 335 patients with ERα-positive breast cancer treated with endocrine therapy. Kaplan–Meier analysis revealed significantly reduced RFS (p < 0.05) in 373 patients with ERα-positive breast cancer with high NgBR expression in tumors as compared to 382 patients with low NgBR expression in tumors. Similarly, RFS in patients with ERα-positive breast cancer treated with endocrine therapy is significantly decreased in 167 patients with high NgBR expression in tumors as compared to 168 patients with low NgBR expression in tumors (p < 0.05). c RFS in patients with ERα-positive breast cancer or endocrine therapy-treated patients. Survivin (BIRC5) mRNA expression data were retrieved from a gene-expression profiling dataset (202094_x from Kaplan–Meier Plot database) of 2046 cases of ERα-positive breast cancer and 928 patients with ERα-positive breast cancer treated with endocrine therapy. Kaplan–Meier analysis revealed significantly reduced RFS (p < 0.05) in 1023 patients with ERα-positive breast cancer with high survivin expression in tumors as compared to 1023 patients with low survivin expression in tumors. Similarly, RFS in patients with ERα-positive breast cancer treated with endocrine therapy is significantly decreased in 463 patients with high survivin expression in tumors as compared to 465 patients with low NgBR expression in tumors (p < 0.05)